Yoshiharu Uruno
Venture capitalist @ JIC Venture Growth Investments
Japan
Yoshiharu Uruno is a Series A investor at JIC Venture Growth Investments in Japan focused on Health Care and Biopharma. Mr. Yoshiharu Uruno is a Venture capitalist at JIC Venture Growth Investments
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Yoshiharu Uruno invests in
Stages Yoshiharu Uruno invests in
Countries Yoshiharu Uruno invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Biopharma 1 (50%)
- Biotechnology 1 (50%)
- Medical Device 1 (50%)
- Virtual Reality 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SiccaNova Therapeutics is a Japanese biopharmaceutical company dedicated to treating sicca (dryness) related medical conditions. The company’s lead drug candidate, XF8302, is a novel, small-molecule M3 muscarine receptor Positive Allosteric Modulator (M3 PAM). Developed initially for dry mouth in Sjögren’s syndrome patients, the drug enhancesnatural acetylcholine signaling to stimulate salivation without the systemic side effects common in traditional agonists. | $7.9M / Series A / Sep 03, 2026 | ||
| BiPSEE is a medical XR company that provides treatment support for children for the purpose of nurturing a sense of self-efficacy. They also deploy AR and VR animation with one button dentistry and medicine, whether outpatient or hospitalized in various situations your child's anxiety and pain relieve. It aims to reduce anxiety and pain inchildren in a wide range of medical fields such as dentistry, pediatrics, and dermatology.BiPSEE is abs ed in Tokyo, Japan. | Series A / Aug 17, 2026 |
Co-Investors
JIC-VGI helps promote innovation and improve its international competitiveness through growth-investments in startup companies. The firm accelerating innovation and helping to solve industrial and social issues by supporting and seeking innovative technologies and new businesses. JIC Venture Growth Investments was established in July 2020 and is based in Tokyo, Japan.
JIC Venture Growth Investments Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hideki Yarimizu
CEO, President & Founder
|
|||
|
Yoshiharu Uruno
Venture capitalist
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Yoshiharu Uruno invest in?
Yoshiharu Uruno invests primarily in Health Care, Biopharma and Biotechnology startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yoshiharu Uruno?
Public channels for Yoshiharu Uruno include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Yoshiharu Uruno last invest?
The most recent investment recorded for Yoshiharu Uruno closed in Sep 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
